cabozantinib

metastatic castration-resistant prostate cancer

Cabometyx

Tecentriq

clinical trials

Exelixis Reports Positive Results in Metastatic Castration-Resistant Prostate Cancer Study

Motley Fool

Wed, 02/12/20 - 10:27 am

metastatic castration-resistant prostate cancer

advanced renal cell carcinoma

Cabometyx

Exelixis Hits Blockbuster Status

Motley Fool

Mon, 08/5/19 - 10:45 am

Exelixis initiates phase 3 trial of cabozantinib in advanced renal cell carcinoma

Pharmaceutical Business Review

Thu, 05/2/19 - 11:20 am

FDA Fast Tracks Calithera Biosciences' CB-839 in Combination with Cabozantinib for Advanced Renal Cell Carcinoma

CP Wire

Wed, 04/18/18 - 07:24 pm

Calithera Biosciences

CB-839

metastatic renal cell carcinoma

2 Big Reasons Exelixis, Inc. Soared 22% in January

Motley Fool

Thu, 02/2/17 - 09:17 am

On a deal spree, Takeda grabs Japanese cabo rights in $145M pact with Exelixis

Endpoints

Tue, 01/31/17 - 09:59 am

3 Things Exelixis Must Do to Survive and Thrive in 2017

Motley Fool

Thu, 11/17/16 - 04:43 pm

Key FDA Decisions and Trial Results Expected in October

24/7 Wall St

Tue, 10/4/16 - 10:07 am

Anthera Pharmaceuticals

Key FDA Decisions and Trial Results Coming in the Next 2 Months

24/7 Wall St

Wed, 09/14/16 - 11:53 pm

Threshold Pharmaceuticals

tarloxotinib

Cerulean Pharma

Vertex Pharmaceuticals

Key FDA Decisions and Trial Results Expected in October

24/7 Wall St

Thu, 09/8/16 - 09:50 am

Anthera Pharmaceuticals

3 Big Pharma Stocks With Credible Threats to Their Blockbusters

24/7 Wall St

Fri, 05/6/16 - 10:52 am

Exelixis Rises on Positive Late-Stage Trial Results

24/7 Wall St

Mon, 02/1/16 - 11:17 pm

FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal Cell Carcinoma in Patients Who Received One Prior Therapy

Yahoo

Mon, 08/24/15 - 11:26 am

FDA

breakthrough therapies

renal cell carcinoma

mirevtuximab soravtansine

6 Key Cancer Winners From ASCO Presentations

24/7 Wall St

Mon, 06/1/15 - 10:06 am

ASCO

Immunogen

sacituzumab govitecan

pacritinib

CTI BioPharma

Exelixis drops 15% after prostate cancer drug candidate fails Phase 3

Seeking Alpha

Mon, 12/1/14 - 11:31 am

Exelixis Drug Fails Pivotal Prostate Cancer Study; Laying Off 70% of Employees

TheStreet.com

Tue, 09/2/14 - 07:54 am

Disappointment Over Prostate Cancer Drug Study Weigh Heavily on Exelixis

TheStreet.com

Wed, 03/26/14 - 12:38 pm

Exelixis achieves enrollment target for phase 3 trial of cabozantinib

Yahoo/Fly on the Wall

Thu, 09/26/13 - 08:19 am

metastatic castration-resistant prostate cancer

Exelixis Announces Presentation of Updated Phase 2 Data for Cabozantinib in Men with Heavily-Pretreated Metastatic Castration-Resistant Prostate Cancer

Yahoo/BusinessWire

Sat, 06/1/13 - 12:17 pm